EC Number   |
Application |
Reference |
|---|
   3.4.24.75 | analysis |
improvement of lipid extraction of staphylococcal cells |
695804 |
| 3.4.24.75 | diagnostics |
detection of Staphylococcus aureus |
695804 |
| 3.4.24.75 | food industry |
antistaphylococcal agent |
695804 |
| 3.4.24.75 | medicine |
a bone morphogenetic protein 2-loaded lysostaphin-delivering hydrogel simultaneously prevents Staphylococcus aureus infection and repairs nonhealing segmental bone defects in the murine radius |
755399 |
| 3.4.24.75 | medicine |
application as effective antibiotic drug against infections with Staphylococcus aureus |
670123 |
| 3.4.24.75 | medicine |
enzyme-functionalized gold and silver nanoparticles are an antibacterial platform for combating methicillin-resistant Staphylococcus aureus bacterial infections |
754815 |
| 3.4.24.75 | medicine |
lysostaphin can be used in combination with clarithromycin for the eradication of Staphylococcus aureus biofilms with a minimal biofilm eradication concentration reduction of 9 and 6fold dilutions on meticillin-resistant S. aureus and meticillin-susceptible S. aureus, respectively |
719602 |
| 3.4.24.75 | medicine |
lysostaphin can be used potentially as a topical disinfectant or decolonizing agent against methicillin-resistant Staphylococcus aureus infection on on human skin prior to operations. The combination is significantly more effective than treatment with ranalexin or lysostaphin alone, overview |
708898 |
| 3.4.24.75 | medicine |
lysostaphin exerts high levels of activity against antibiotic-resistant strains of Staphylococcus aureus |
733114 |
| 3.4.24.75 | medicine |
lysostaphin has potential for use as an antistaphylococcal agent for treatment of infections caused by antibiotic-resistant strains of Staphylococcus aureus |
718632 |
